Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Cash from Financing Activities (2017 - 2025)

Crinetics Pharmaceuticals has reported Cash from Financing Activities over the past 9 years, most recently at $26.0 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $26.0 million for Q4 2025, down 95.32% from a year ago — trailing twelve months through Dec 2025 was $40.6 million (down 96.0% YoY), and the annual figure for FY2025 was $40.6 million, down 96.0%.
  • Cash from Financing Activities for Q4 2025 was $26.0 million at Crinetics Pharmaceuticals, up from $3.1 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for CRNX hit a ceiling of $556.2 million in Q4 2024 and a floor of $57000.0 in Q1 2021.
  • Median Cash from Financing Activities over the past 5 years was $14.1 million (2021), compared with a mean of $91.1 million.
  • Biggest five-year swings in Cash from Financing Activities: surged 168823.71% in 2021 and later plummeted 99.93% in 2022.
  • Crinetics Pharmaceuticals' Cash from Financing Activities stood at $163.9 million in 2021, then plummeted by 99.93% to $115000.0 in 2022, then soared by 34870.43% to $40.2 million in 2023, then skyrocketed by 1283.12% to $556.2 million in 2024, then tumbled by 95.32% to $26.0 million in 2025.
  • The last three reported values for Cash from Financing Activities were $26.0 million (Q4 2025), $3.1 million (Q3 2025), and $7.1 million (Q2 2025) per Business Quant data.